Navigation Links
U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain
Date:11/9/2009

Neurologists will use funds to move lab findings into human therapy for difficult-to-treat condition that involves pain from nerve damage

ANN ARBOR, Mich., Nov. 9 /PRNewswire-USNewswire/ --Researchers from the University of Michigan Department of Neurology have received a $1.8 million grant to develop a novel therapy for neuropathic pain, a difficult-to-treat condition in which patients experience pain because of damage to nerve without obvious tissue injury.

In previously published studies, these investigators have found that gene transfer to sensory nerves using a modified herpes simplex virus-based vector effectively reduced pain-related behaviors in rodents with nerve damage caused by trauma or diabetes. A gene transfer vector is an agent used to carry genes into cells.

The newly awarded grant from the Department of Veterans Affairs will allow the investigators to produce and certify a human grade vector that will then be tested in patients with pain from nerve damage resulting from diabetes.

"This grant will allow us to take the critical step in translating laboratory findings into human therapy," says principal investigator David Fink, M.D., Robert Brear professor and chair of the Department of Neurology. Fink is also a staff neurologist at the VA Ann Arbor Healthcare System.

Fink and his collaborators have previously demonstrated that gene transfer vectors created from recombinant crippled herpes simplex viruses can be used to deliver genes to sensory nerves from application in the skin.

Fink is directing a phase 1 human trial on the first such vector carrying the gene for human preproenkephalin in patients with intractable pain from cancer. The second trial will test a vector carrying the gene for glutamic acid decarboxylase that has proven to be particularly effective in animal models of neuropathic pain.

"We are very excited to receive this grant," says co-investigator Dr. Marina Mata, M.D., also a professor of Neurology.

"We routinely create new vectors and produce them in the laboratory for animal studies, but in order to have a vector that is approved for human use requires a series of extraordinarily expensive steps. This grant should allow us to begin the human trial in patients with painful diabetic neuropathy within two years."

Construction of the vector will be carried out under contract by Diamyd, Inc. of Pittsburgh, PA. Diamyd is funding the phase 1 trial of the preproenkephalin vector, and has licensed the patents to the vector technology.

The researchers believe that the use of HSV vectors holds promise not only for the treatment of pain but also ultimately for the treatment of peripheral neuropathy itself.

Fink has received research funding from Diamyd related to the human trial of the preproenkephalin vector. He has no equity interest in nor any consulting agreements with Diamyd.

SOURCE University of Michigan Health System


'/>"/>
SOURCE University of Michigan Health System
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers show how to divide and conquer social network of cells
2. Connection between depression and osteoporosis detailed by Hebrew University researchers
3. Researchers find new way to attack inflammation in Graves eye disease
4. Jefferson researchers receive $3.9 million in Challenge grants
5. Childhood cancer survivors less likely to marry, Yale researchers find
6. Researchers unlock the sound of learning by linking sensory and motor systems
7. Researchers identify the 3 killer indicators that are even worse than high cholesterol
8. Researchers discover links between city walkability and air pollution exposure
9. High-definition colonoscopy detects more polyps, Mayo Clinic researchers say
10. Researchers find room design can enhance patient care
11. UC San Diego researchers reverse pulmonary arterial hypertension in mouse models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... ... Star Glass is new to the Texas market, but is proudly managed by widely recognized ... and models, in Grand Prairie, TX, located in the center of the DFW Metroplex, the ... business for the past 40 years with 32 convenient locations in Texas, Nevada and California ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: ... creation of published author, Julianne Hale, a consultant for the Intelligence Community. ... expert focusing on the Near East region. Julianne has written hundreds of ...
(Date:8/22/2017)... ... 22, 2017 , ... “Call Of Spiritual Duty”: a revelation in an era ... C.S. Lizarde. Growing up on the streets of North Visalia, California, Carlos Lizarde ... apply the Biblical keys to his life, he noticed immediately that opportunities and blessings ...
(Date:8/21/2017)... ... August 22, 2017 , ... The ... as a 2017-2018 inductee into its VIP Woman of the Year Circle. She ... nation’s leading networking organization exclusively for professional women, boasting more than 850,000 members, ...
(Date:8/21/2017)... , ... August 21, 2017 , ... Five chefs from ... awareness for Alzheimer’s Family Center. , Guests will be able to vote for ... Plaza, Braised Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... Israel , Aug. 15, 2017 /PRNewswire/ ... of adult stem cell technologies for neurodegenerative diseases, announced ... 2017. "We are ... Phase 3 trial to investigate NurOwn ® in ... Executive Officer of BrainStorm. "We have agreements with Mass. ...
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), acquired ... Lakewood, Colorado . The reputable clinic will ... , PT, DPT with his staff of four clinicians. Lipkin ... Pittsburgh and brings over 10 years of experience with a ... Belmar PT marks the 10th PRN clinic in and around ...
(Date:8/8/2017)...   Second-quarter 2017 revenues of ... share from continuing operations ... to $110 million Second-quarter ... million Second-quarter 2017 adjusted ... 8 percent to $0.93 ...
Breaking Medicine Technology: